SCHEMBL2826368

SCHEMBL2826368

CCc1nc(N2CC(N)C2)sc1C(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
KDM4E B2RXH2 4/20 0.34
ALDH1A1 P00352 4/20 0.34
GAA P10253 2/20 0.34
HSD17B10 Q99714 3/20 0.33
PABPC1 P11940 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
HPGD P15428 3/20 0.32
POLB P06746 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
TSHR P16473 2/20 0.32
TP53 P04637 1/20 0.31
IKBKB O14920 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2826922 0.83 DRD3 (0.38) MAPTSMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL5521763 0.80 MAPT (0.38) MAPTSMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL2824168 0.75 MEN1 (0.32) MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL2822554 0.75 ALDH1A1 (0.51) MAPTSMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL2822071 0.73 MAPT (0.34) MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL2822535 0.73 MEN1 (0.31) MAPTSMN1; SMN2KMT2AMEN1TP53
SCHEMBL16404871 0.72 PIK3CD (0.40) MAPTSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL1540028 0.72 ALDH1A1 (0.49) MAPTSMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL2823244 0.71 ALDH1A1 (0.44) MAPTSMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL2825372 0.70 KMT2A (0.47) MAPTKMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2226322-B1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO CO LTD (JP) 2015-01-21 EP disclosed
US-8927588-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-06 US disclosed
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
US-8536197-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-17 US disclosed
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-12-09 US disclosed
EP-2226322-A1 IMIDAZOLE CARBONYL COMPOUND Daiichi Sankyo Company, Limited (JP) 2010-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A MAPT 1455/4885SMN1; SMN2 4001/4885KMT2A 847/4885
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A MAPT 1979/4885SMN1; SMN2 3604/4885KMT2A 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.